Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is strategically leveraging its advanced pipeline, strong clinical data, and differentiated C5aR inhibition technology to pursue multiple opportunities in autoimmune and inflammatory diseases. Recent news of a pipeline shift, increased cash position, and plans to assertively pursue development of izicopan in ANCA vasculitis signal strong potential for the stock. In addition to its potential in ANCA vasculitis, izicopan shows promise in addressing high unmet needs in other indications such as AAV, IgAN, FSGS, and more, and could generate significant value through M&A activities.

Bears say

InflaRx is currently conducting Phase 2 trials for their product candidate izicopan targeting various inflammatory renal diseases, but there may be potential challenges and toxicity signals associated with C5a/C5aR inhibition. The company is also planning for potential approval and considering a single Phase 2/3 trial to conserve resources. However, their current cash position is expected to provide runway through 2029 and they have potential for a differentiated offering in the AAV market.

InflaRx (IFRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 6 analysts, InflaRx (IFRX) has a Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.